STERIS plc (STE) Stock Analysis and Metrics

Steris

NYSE: STE

$218.86 ▲ +4.79 (+2.24%)

At close: Jul 27, 2026 · 3:49 PM UTC

Financial Ratios

Market Cap21.45 Bn

P/S3.61

Div. Yield0.01

ROIC (Qtr)0.07

Total Debt (Qtr)1.93 Bn

Revenue Growth (1y) (Qtr)7.29

Add ratio to table…

About

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company helps its customers create a healthier and safer world by delivering innovative healthcare and life science products and services around the globe.

STERIS generates revenue through a diversified mix of consumable products, services, capital equipment and connectivity solutions. Its consumable offerings include detergents, endoscopy accessories, barrier products, instruments, and tools. Services encompass equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing. Capital equipment comprises sterilizers, surgical tables, and automated endoscope reprocessors. Connectivity solutions provide operating room integration to enhance workflow efficiency.

STERIS operates through three reportable business segments: Healthcare, Applied Sterilization Technologies (AST) and Life Sciences.

• Healthcare: This segment provides a comprehensive offering for healthcare providers worldwide, focusing on sterile processing departments and procedural centers such as operating rooms and endoscopy suites. Its product range includes cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, tracking products, endoscopy accessories, instruments, washers, sterilizers, surgical tables, lights, and equipment management services. Service offerings consist of equipment installation, maintenance, upgrade, repair and troubleshooting, preventive maintenance programs, instrument and endoscope repair and maintenance, custom process improvement consulting, and outsourced instrument sterile processing.

• AST: This segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities and integrated sterilization equipment and control systems. It offers a wide range of sterilization modalities and testing services that complement the manufacturing of single use sterile products. The segment also manufactures and supplies process controls, monitoring systems, and integrated sterilization equipment including accelerators, product handling, and automation.

• Life Sciences: This segment provides a comprehensive offering of products and services to support biopharmaceutical and medical device manufacturing facilities with a focus on aseptic manufacturing. Its product portfolio includes pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems, sterilizers, high purity water, and pure steam generators. Service offerings consist of equipment installation, maintenance, upgrade, repair and troubleshooting, preventive maintenance programs, and repair services.

STERIS holds a strong position in the infection prevention and sterilization markets, competing with a variety of large and small companies across its segments. In the Healthcare segment, key competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron, and Wassenburg. For the AST segment, primary competitors are Sterigenics International, other contract sterilization firms, manufacturers of sterilization equipment and control systems, and companies that perform sterilization in house. In the Life Sciences segment, rivals consist of Belimed, Contec, Ecolab, Fedegari, Getinge, and Stilmas. The company’s competitive advantages stem from its broad product and service portfolio, global reach, strong investment in research and development, commitment to quality and ability to provide integrated solutions that improve efficiency and safety for customers.

The bulk of STERIS’s revenue comes from healthcare, medical device and pharmaceutical customers. These customers include hospitals, ambulatory surgery centers, endoscopy suites, medical device manufacturers, pharmaceutical manufacturers, and biopharmaceutical research facilities. No single customer accounts for more than ten percent of any segment’s revenue, indicating a diversified base.

Investment Thesis

▲ Bull case

STERIS possesses a fundamentally resilient business model underpinned by its critical role in healthcare infection prevention and procedural volume growth, which remains structurally sound despite near-term inventory adjustments by med-tech customers. While management acknowledged softer AST service performance in Q4 due to weather-related disruptions and cited cautious med-tech inventory management, the underlying demand remains intact as evidenced by consistent mid-single digit growth in U.S. procedure volumes and strong top-line sales from large public med-tech companies. This inventory drawdown represents a temporary, cyclical headwind rather than a structural demand deterioration, creating a significant upside opportunity when restocking cycles normalize. The company’s ability to generate over $1 billion in adjusted net income on $6 billion in revenue demonstrates exceptional scale and profitability, with Healthcare segment operating income exceeding $1 billion for the first time—a milestone that reflects deepening customer partnerships and operational integration. Furthermore, the vertical integration of MEDglas walls supplier not only secures supply for a differentiated product but also enhances gross margins through reduced third-party dependency, even if the product itself is lower-margin, by improving overall OR and SPD workflow efficiency and customer stickiness. This strategic move, combined with the tuck-in GI product acquisition adding established sales reps and channel access, positions STERIS to capture incremental share in high-growth procedural areas without relying on large, dilutive M&A. The market may be underestimating how these targeted, bolt-on investments compound over time to drive sustainable mid- to high-single digit organic growth while improving segment profitability through better product mix and service attachment rates.
STERIS’s capital allocation discipline and balance sheet strength create a powerful compounding engine that the market is overlooking amid near-term margin pressure from tariffs and inflation. Despite guiding to only 50 basis points of EBIT margin expansion in FY27, the company generated $982.9 million in free cash flow in FY26—a 34% free cash flow yield on its $2.9 billion market cap—while maintaining gross debt to EBITDA at a conservative 1.2x, well below its 2.0x–2.5x target. This extraordinary cash conversion, driven by earnings growth more than offsetting working capital headwinds, provides substantial dry powder for shareholder returns and strategic investments. The board’s approval of a new $1 billion share buyback authorization, coupled with guidance to deploy $200–$300 million annually, represents a significant escalation in capital return potency, especially given the stock’s recent underperformance relative to peers. Critically, while management highlighted the withholding tax hurdle on buybacks due to offshore profit repatriation, they also confirmed that consistent execution reduces the incremental tax burden over time as the geographic profit mix stabilizes—meaning the effective drag diminishes with scale. Additionally, the planned $60 million investment over two years for a new sterility assurance manufacturing plant in Mentor, Ohio, will consolidate fragmented U.S. production into a highly automated center of excellence, unlocking long-term operating leverage and margin expansion in a high-growth, high-margin business that already exceeds $500 million in operating profit within AST. This facility, expected operational by end-2027, is not merely a cost-saving project but a strategic enabler for sustained double-digit growth in a defensible niche, with benefits likely to accrue faster than modeled due to automation-driven quality and throughput improvements.

STERIS possesses a fundamentally resilient business model underpinned by its critical role in healthcare infection prevention and procedural volume growth, which remains structurally sound despite near-term inventory adjustments by med-tech customers. While management acknowledged softer AST service performance in Q4 due to weather-related disruptions and cited cautious med-tech inventory management, the underlying demand remains intact as evidenced by consistent mid-single digit growth in U.S. procedure volumes and strong top-line sales from large public med-tech companies. This inventory drawdown represents a temporary, cyclical headwind rather than a structural demand deterioration, creating a significant upside opportunity when restocking cycles normalize. The company’s ability to generate over $1 billion in adjusted net income on $6 billion in revenue demonstrates exceptional scale and profitability, with Healthcare segment operating income exceeding $1 billion for the first time—a milestone that reflects deepening customer partnerships and operational integration. Furthermore, the vertical integration of MEDglas walls supplier not only secures supply for a differentiated product but also enhances gross margins through reduced third-party dependency, even if the product itself is lower-margin, by improving overall OR and SPD workflow efficiency and customer stickiness. This strategic move, combined with the tuck-in GI product acquisition adding established sales reps and channel access, positions STERIS to capture incremental share in high-growth procedural areas without relying on large, dilutive M&A. The market may be underestimating how these targeted, bolt-on investments compound over time to drive sustainable mid- to high-single digit organic growth while improving segment profitability through better product mix and service attachment rates.
STERIS’s capital allocation discipline and balance sheet strength create a powerful compounding engine that the market is overlooking amid near-term margin pressure from tariffs and inflation. Despite guiding to only 50 basis points of EBIT margin expansion in FY27, the company generated $982.9 million in free cash flow in FY26—a 34% free cash flow yield on its $2.9 billion market cap—while maintaining gross debt to EBITDA at a conservative 1.2x, well below its 2.0x–2.5x target. This extraordinary cash conversion, driven by earnings growth more than offsetting working capital headwinds, provides substantial dry powder for shareholder returns and strategic investments. The board’s approval of a new $1 billion share buyback authorization, coupled with guidance to deploy $200–$300 million annually, represents a significant escalation in capital return potency, especially given the stock’s recent underperformance relative to peers. Critically, while management highlighted the withholding tax hurdle on buybacks due to offshore profit repatriation, they also confirmed that consistent execution reduces the incremental tax burden over time as the geographic profit mix stabilizes—meaning the effective drag diminishes with scale. Additionally, the planned $60 million investment over two years for a new sterility assurance manufacturing plant in Mentor, Ohio, will consolidate fragmented U.S. production into a highly automated center of excellence, unlocking long-term operating leverage and margin expansion in a high-growth, high-margin business that already exceeds $500 million in operating profit within AST. This facility, expected operational by end-2027, is not merely a cost-saving project but a strategic enabler for sustained double-digit growth in a defensible niche, with benefits likely to accrue faster than modeled due to automation-driven quality and throughput improvements.

▼ Bear case

STERIS faces mounting margin pressure from persistent macroeconomic headwinds that management is inadequately addressing, particularly the compounding impact of tariffs and inflation on its cost structure, which could erode profitability despite revenue growth. While the company guided to flat year-over-year tariff spending in FY27 and cited favorable recent changes as a “bonus tailwind” of approximately $2 million, it simultaneously acknowledged that incremental tariffs in FY26 totaled $46 million—contributing to an 80 basis point margin headwind—and that total tariff spend remains modeled between $60 million and $65 million annually. This implies that any relief from recent policy shifts is marginal and insufficient to offset the structural cost burden, especially as energy-driven costs (representing ~20% of COGS across raw materials and freight) remain exposed to oil price volatility. Management downplayed energy’s impact as “low single digits” for fleet fuel and noted only partial raw material exposure, but failed to quantify how sustained high oil prices could pressure logistics and input costs beyond their assumed upward pressure cushion. Furthermore, the reliance on freight recovery pricing to mitigate customer-facing costs introduces execution risk, as success depends on contractual leverage and customer willingness to absorb increases—factors not discussed in detail. With inflation assumptions described as “measured” and tied to oil-driven materials, the guidance appears vulnerable to a scenario where prolonged geopolitical tensions keep energy costs elevated, directly squeezing margins in both Healthcare and AST segments, where consumables and service profitability are critical to overall performance.
STERIS’s growth outlook is overly dependent on procedural volume recovery and med-tech inventory restocking, which may be delayed or weaker than anticipated due to lingering healthcare system capital constraints and shifting customer priorities, creating a significant risk to its FY27 organic growth targets of 6%–7%. Management conceded that AST service growth was hampered by difficult comps from prior-year double-digit performance and weather-related disruptions, expecting a softer first half before improvement in H2—a tacit admission that near-term growth is back-end loaded and fragile. More concerning is the admission that med-tech customers are actively managing inventory levels carefully, a trend tied to broader healthcare sector pressure to reduce operating expenses and optimize working capital, which could prolong the inventory drawdown beyond temporary weather effects. While procedure volumes continue to grow mid-single digits, the disconnect between rising procedures and falling STERIS volumes suggests that customers are either delaying product purchases, shifting to competitors, or utilizing existing stock more efficiently—none of which bode well for sustained organic growth. The Life Sciences segment, though showing strength in consumables (8% growth) and capital equipment recovery (15% growth), remains heavily reliant on big pharma reshoring trends, with management openly acknowledging a lack of investment in smaller players—a segment not aligned with STERIS’s sweet spot. This concentration risk, combined with the cautious tone on AST and the reliance on tuck-in M&A for incremental revenue ($45 million, or ~100 basis points of Healthcare growth), suggests that organic expansion may struggle to meet expectations without larger, riskier acquisitions that management has historically avoided. The market may be ignoring how these demand-side uncertainties, coupled with modest inorganic contributions, could result in growth that falls short of the lower end of guidance, especially if healthcare systems prioritize cost containment over procedural expansion in an uncertain economic environment.

STERIS faces mounting margin pressure from persistent macroeconomic headwinds that management is inadequately addressing, particularly the compounding impact of tariffs and inflation on its cost structure, which could erode profitability despite revenue growth. While the company guided to flat year-over-year tariff spending in FY27 and cited favorable recent changes as a “bonus tailwind” of approximately $2 million, it simultaneously acknowledged that incremental tariffs in FY26 totaled $46 million—contributing to an 80 basis point margin headwind—and that total tariff spend remains modeled between $60 million and $65 million annually. This implies that any relief from recent policy shifts is marginal and insufficient to offset the structural cost burden, especially as energy-driven costs (representing ~20% of COGS across raw materials and freight) remain exposed to oil price volatility. Management downplayed energy’s impact as “low single digits” for fleet fuel and noted only partial raw material exposure, but failed to quantify how sustained high oil prices could pressure logistics and input costs beyond their assumed upward pressure cushion. Furthermore, the reliance on freight recovery pricing to mitigate customer-facing costs introduces execution risk, as success depends on contractual leverage and customer willingness to absorb increases—factors not discussed in detail. With inflation assumptions described as “measured” and tied to oil-driven materials, the guidance appears vulnerable to a scenario where prolonged geopolitical tensions keep energy costs elevated, directly squeezing margins in both Healthcare and AST segments, where consumables and service profitability are critical to overall performance.
STERIS’s growth outlook is overly dependent on procedural volume recovery and med-tech inventory restocking, which may be delayed or weaker than anticipated due to lingering healthcare system capital constraints and shifting customer priorities, creating a significant risk to its FY27 organic growth targets of 6%–7%. Management conceded that AST service growth was hampered by difficult comps from prior-year double-digit performance and weather-related disruptions, expecting a softer first half before improvement in H2—a tacit admission that near-term growth is back-end loaded and fragile. More concerning is the admission that med-tech customers are actively managing inventory levels carefully, a trend tied to broader healthcare sector pressure to reduce operating expenses and optimize working capital, which could prolong the inventory drawdown beyond temporary weather effects. While procedure volumes continue to grow mid-single digits, the disconnect between rising procedures and falling STERIS volumes suggests that customers are either delaying product purchases, shifting to competitors, or utilizing existing stock more efficiently—none of which bode well for sustained organic growth. The Life Sciences segment, though showing strength in consumables (8% growth) and capital equipment recovery (15% growth), remains heavily reliant on big pharma reshoring trends, with management openly acknowledging a lack of investment in smaller players—a segment not aligned with STERIS’s sweet spot. This concentration risk, combined with the cautious tone on AST and the reliance on tuck-in M&A for incremental revenue ($45 million, or ~100 basis points of Healthcare growth), suggests that organic expansion may struggle to meet expectations without larger, riskier acquisitions that management has historically avoided. The market may be ignoring how these demand-side uncertainties, coupled with modest inorganic contributions, could result in growth that falls short of the lower end of guidance, especially if healthcare systems prioritize cost containment over procedural expansion in an uncertain economic environment.

Segments Breakdown of Revenue (2026)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	182.52 Bn	29.08	4.04	34.05 Bn
2	SYK	Stryker Corp	128.96 Bn	38.65	5.10	14.72 Bn
3	MDT	Medtronic plc	107.99 Bn	22.32	2.97	27.96 Bn
4	BSX	Boston Scientific Corp	67.76 Bn	19.01	3.29	11.03 Bn
5	EW	Edwards Lifesciences Corp	48.09 Bn	2,334.23	7.63	0.60 Bn
6	DXCM	Dexcom Inc	28.30 Bn	30.41	5.87	-
7	GEHC	GE HealthCare Technologies Inc.	27.89 Bn	14.11	1.33	10.14 Bn
8	SNN	Smith & Nephew Plc	27.02 Bn	161.82	4.19	3.18 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Segments Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Segments Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password